The DOI matches its Crossref record; 202 of the 217 references it cites were found in a registry or an index; 71 of the 117 sources its claims cite were checked for support.
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Open accessAbstract
In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people. With 55 million people affected, the WHO considers AD to be a disease with public priority. Unfortunately, there are no final cures for this pathology. Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, the best approaches for managing the disease seem to combine pharmacological and non-pharmacological therapies to stimulate cognitive reserve. Over the last twenty years, a number of drugs have been discovered acting on the well-established biological hallmarks of AD, deposition of β-amyloid aggregates and accumulation of hyperphosphorylated tau protein in cells. Although previous efforts disappointed expectations, a new era in treating AD has been working its way recently. The Food and Drug Administration (FDA) gave conditional approval of the first disease-modifying therapy (DMT) for the treatment of AD, aducanumab, a monoclonal antibody (mAb) designed against Aβ plaques and oligomers in 2021, and in January 2023, the FDA granted accelerated approval for a second monoclonal antibody, Lecanemab. This review describes ongoing clinical trials with DMTs and non-pharmacological therapies. We will also present a future scenario based on new biomarkers that can detect AD in preclinical or prodromal stages, identify people at risk of developing AD, and allow an early and curative treatment.
Overview
CoChat Summary
## TL;DR
This is a narrative review of Alzheimer’s disease (AD) treatment beyond symptomatic therapy, focusing on disease-modifying treatments, stem cells, and non-pharmacological interventions. It argues that earlier diagnosis with biomarkers and earlier treatment are key, and it highlights recent antibody approvals such as aducanumab and lecanemab.
## Key findings
- The review states that the estimated number of people with AD dementia is about 50 million worldwide, and that this may rise to 150 million by 2050.
- It says the current symptomatic drugs are acetylcholinesterase inhibitors and memantine, which provide temporary relief but do not cure AD.
- In phase III clinical trials, the authors report 36 agents in the AD pipeline, of which 25% are DMT-biologics, 42% are DMT small molecules, and 7 agents (19% of the total DMTs) are monoclonal antibodies targeting different parts of Aβ.
- The review reports multiple trial outcomes: donanemab slowed cognitive decline by 40% on the iADRS in TRAILBLAZER-ALZ 2; lecanemab produced moderately less decline at 18 months in early AD; gantenerumab failed to meet primary endpoints; and solanezumab failed in completed phase 3 trials.
## Methods
- Narrative literature review of AD treatments “beyond symptomatic therapies,” covering immunotherapy, disease-modifying treatments, stem cells, and non-pharmacological interventions.
- The authors draw on published studies and clinical trial listings from ClinicalTrials.gov; no original patient sample or new dataset is reported.
- Main analysis is descriptive synthesis of trial and preclinical evidence, with discussion of trial design issues, biomarker use, and developmental status of therapies.
## Limitations
- The paper itself does not state formal study limitations; it is a review rather than an empirical study.
- Evident limitation: the conclusions depend on heterogeneous evidence from preclinical studies, phase II/III trials, and trial registries, rather than a systematic meta-analysis or newly collected data.
- Evident limitation: several treatment sections are incomplete or only mention ongoing trials, so for some agents the paper cannot provide outcome data yet.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
46 Valid · 4 Not valid · 20 Not checked · 6 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Supportedcites [4] Selkoe, 2016, The amyloid hypothesis of Alzheimer’s disease at 25 years, EMBO Mol. Med. source
The Introduction describes Aβ aggregation and deposition followed by tau-related changes, neuronal dysfunction, and clinical dementia. The section “Connecting plaques and tangles” also states that Aβ accumulation can lead to progressive tau deposition. Page numbers were not supplied in our copy. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [5] Fontana, 2020, Amyloid-β oligomers in cellular models of Alzheimer’s disease, J. Neurochem. source
- Supportedcites [6] Cline, 2018, The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade, J. Alzheimer’s Dis. source
The Introduction (page unavailable) says Aβ oligomers cause tau pathology, nerve-cell death, and cognitive loss, and describes neuronal damage leading to dementia. The tau-progression section (page unavailable) reports synaptic Aβ oligomers and phosphorylated tau in AD brains. Together, these support the broad paraphrase, although the paper emphasizes Aβ oligomers as the proposed upstream driver. (LLM, conf=0.84)
- Partly supportedcites [7] Hayden, 2013, Amyloid β-protein oligomers and Alzheimer’s disease, Alzheimer’s Res. Ther. sourceExperimental — accuracy not yet measured
The Introduction describes Aβ deposits and oligomers in AD and links loss of cognitive function to synaptic damage and neuronal loss. The ‘Oligomer characterization in vivo’ section reports tau accumulation and cognitive decline together in a mouse model, but the paper does not establish that misfolded Aβ and tau both accumulate in the human AD brain as a single causal cascade leading to dementia. (LLM, conf=0.84)
- Supportedcites [8] Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., and Lewczuk, P. (2018). Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease. Int. J. Mol. Sci., 19. source
The Introduction identifies Aβ plaques and phosphorylated Tau tangles as hallmarks of AD and states that progressive neuronal and synaptic damage leads to cognitive impairment and dementia. Sections 2.6 and 2.8 describe Tau aggregation and Aβ-related pathological processes, supporting the claim’s description of a neurodegenerative cascade. (LLM, conf=0.91)
- Supportedcites [9] Noble, 2016, Amyloid-β Receptors: The Good, the Bad, and the Prion Protein, J. Biol. Chem. source
The Introduction describes Aβ plaques and tau tangles in the AD brain. It also presents the amyloid cascade hypothesis, in which Aβ-driven pathology is followed by cell loss and dementia, and reports an interpretation in which Aβ aggregation triggers tau aggregation and neurodegeneration. This supports the citing sentence as a broad description of the proposed cascade. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Not checked — no full text of the sourcecites [10] Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer’s disease, Neuron source
- Partly supportedcites [11] Freir, 2010, Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says therapeutic targeting of Aβ dimers remains attractive because it should prevent formation of toxic pre-fibrillar assemblies. This supports a possible treatment strategy, but the paper does not specify treatment in the early stages of AD or establish that broadly reducing soluble aggregates is practical. (LLM, conf=0.85)
- Supportedcites [12] Lacor, 2004, Synaptic targeting by Alzheimer’s-related amyloid beta oligomers, J. Neurosci. source
The Discussion (page not provided) proposes neutralizing early pathogenic events and reports that antibodies against soluble Aβ species reversed memory loss in mouse models of early AD. It describes the prospects for therapeutic antibodies targeting these assemblies as encouraging, while noting complications with active vaccination. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Not checked — no full text of the sourcecites [10] Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer’s disease, Neuron source
- Partly supportedcites [11] Freir, 2010, Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion describes non-fibrillar, water-soluble Aβ as the principal mediators of neurotoxicity, and the Results show that soluble protofibrils inhibit synaptic plasticity. The paper does not directly compare their toxicity with that of monomers or insoluble mature fibrils, so the full comparative claim is not established. (LLM, conf=0.82)
- Partly supportedcites [12] Lacor, 2004, Synaptic targeting by Alzheimer’s-related amyloid beta oligomers, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page not available) describes soluble Aβ oligomers as neurologically harmful and potent CNS neurotoxins. The ‘Synthetic oligomeric species bind specifically to clustered sites’ section reports that larger oligomers bound hippocampal dendrites whereas a fraction containing monomers and small oligomers did not. The paper does not establish that soluble aggregates are more toxic than insoluble fibrils, and the binding result is not a direct toxicity comparison with monomers. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Supportedcites [4] Selkoe, 2016, The amyloid hypothesis of Alzheimer’s disease at 25 years, EMBO Mol. Med. source
The section “Connecting plaques and tangles” calls plaques and tangles the two canonical lesions of Alzheimer’s disease. The biomarker section likewise refers to them as the two major lesions, and the Abstract identifies neuritic plaques as deposits of amyloid fibrils. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Donanemab significantly slowed the clinical progression in individuals with early symptomatic AD and amyloid and tau pathology.”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 4. State of the Art of AD Disease-Modifying Treatments (DMT)s > 4.1. mAbs Anti-Aβ and Anti-Tau
What the sources say
- Supportedcites [68] Sims, 2023, Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, JAMA source
The Abstract conclusions state that donanemab significantly slowed clinical progression at 76 weeks among participants with early symptomatic Alzheimer disease and amyloid and tau pathology. The Primary Outcome section also reports statistically significant slowing versus placebo in both the low/medium tau and combined tau populations. (LLM, conf=0.95)
- Could not verifycites [69] Wessels, 2015, A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer’s Disease Rating Scale (iADRS), J. Prev. Alzheimer’s Dis. sourceExperimental — accuracy not yet measured
The Results > Therapeutic Sensitivity passage reports reduced decline with solanezumab in mild AD, not donanemab. Searches for donanemab and for early symptomatic AD with amyloid and tau pathology found no passage in our copy addressing the attributed finding; page numbers were not available. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 22 with their cited sources checked
Create a free account to see all 76 claims and to verify the 4 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“In particular, the resulting complex, activating ERK and JNK1 kinases, which hyperphosphorylated tau protein, prevented the tau microtubule stabilization and contributed to neuronal dysfunction and degeneration [160,161].”
Cited work 10.1016/j.neurobiolaging.2017.03.016 · retracted 2017-07-01 · notice 10.1016/j.neurobiolaging.2017.03.016 · this paper published 2023-09-09
Citations
Cites
1 retracted
Wang, H.-Y., Lee, K.-C., Pei, Z., Khan, A., Bakshi, K. P., & Burns, L. H. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.016 · Cited by 55 · cited 2×
“In particular, the resulting complex, activating ERK and JNK1 kinases, which hyperphosphorylated tau protein, prevented the tau microtubule stabilization and contributed to neuronal dysfunction and degeneration [160,161].”
BackgroundRetractedNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 7×
“The A β oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic A β oligomers rather than amyloid plaques as key players in AD pathogenesis [4–7].”
BackgroundInfluentialLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575 · cited 2×
“This number will increase to 150 million by 2050 [1,2].”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of A β [4–7 , 18].”
BackgroundActivation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274 · cited 1×
“Among them, MAPK signaling is activated in the early stages of immune activation [132].”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cited by
Oxidative stress–mediated neuroinflammation in Alzheimer’s disease
Firdous, S. M., Khan, S. A., & Maity, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03188-3 · Cited by 98
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 55
“…treatment of Alzheimer’s disease; i /inhibitors of the enzyme cholinesterase, i.e., donepezil, rivastigmine, or galantamine, and ii /N-methyl-D-aspartate antagonists, i.e., memantine, which are only effective in treating the symptoms of the disease but do not cure or prevent the disease [88,114].”
Ureña-Vacas, I., Belén, A. D. L. R. M., Serrano, D. R., & González‐Burgos, E. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100235 · Cited by 46
Arroyo-Pacheco, N., Sarmiento-Blanco, S., Vergara-Cadavid, G., Castro-Leones, M., & Contreras‐Puentes, N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102620 · Cited by 42
Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)
Wanionok, N. E., Morel, G. R., & Fernández, J. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102408 · Cited by 32
Metadata
- Authors
- Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy
- Corresponding author
- Buccellato, Francesca R.
- D’Anca, Marianna
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-09
- Volume
- 24
- Issue
- 18
- Pages
- 13900
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10531090
- OpenAlex
- W4386602162
- Cited by
- 94
- References
- 217
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 31 · 2023: 2
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Italian Ministry of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying therapy, aducanumab, lecanemab, acetylcholinesterase inhibitors, memantine, amyloid plaques, tau hyperphosphorylation, cognitive reserve, non-pharmacological treatment, biomarkers, prodromal Alzheimer's disease, clinical trials
- MeSH terms
- Acetylcholinesterase, Aged, Alzheimer Disease, Antibodies, Monoclonal, Humans, Memantine, United States, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. https://app.cochat.ai/papers/10.3390/ijms241813900
- The paper
- Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023). Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
